Literature DB >> 18679818

Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma.

Ambrosi Pertia1, David Nikoleishvili, Omar Trsintsadze, Nino Gogokhia, Laurent Managadze, Archil Chkhotua.   

Abstract

The goal of the study was to evaluate expression of the cell-cycle regulatory proteins (p27(Kip1) and cyclin D3) and proliferation marker Ki67 in normal human kidneys and renal cell carcinoma (RCC) tissues. Intensity of the markers' expression was prospectively studied and compared between normal and RCC tissue samples. Association was analyzed with cancer clinical parameters. p27(Kip1) was significantly upregulated in normal compared with in RCC samples. Immunoreactivity of the protein negatively correlated with tumor size and was associated with pathological stage and grade. Patients with symptomatic disease had significantly less marker expression than those with incidentally discovered tumors. Intensity of Ki67 staining positively correlated with primary tumor size and associated with disease stage and grade. Cyclin D3 immunoreactivity positively correlated with tumor size. Loss of p27(Kip1) expression, pathological stage, grade, and tumor size were risk factors for disease recurrence (P = 0.0072, 0.0011, and 0.0467, and P < 0.0001, respectively) and patient death (P = 0.0021, 0.0106, 0.0151, and 0.0021, respectively). With Cox multivariate analysis loss of p27(Kip1) expression (hazard ratio 9.3, P = 0.002) and tumor size (hazard ratio 5.9, P = 0.015) were the predictors of cancer-specific survival. In conclusion, intensity of the markers' expression in RCC is associated with tumour clinical parameters (size, stage, grade, and disease presentation type). Loss of p27(Kip1) expression is a risk factor for the disease recurrence and cancer-related patient death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679818     DOI: 10.1007/s11255-008-9442-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  27 in total

1.  Tumor markers for renal cell carcinoma.

Authors:  E Oosterwijk
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

2.  Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma.

Authors:  N Rioux-Leclercq; B Turlin; J Bansard; J Patard; A Manunta; J P Moulinoux; F Guillé; M P Ramée; B Lobel
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

3.  p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.

Authors:  Kyriakos Revelos; Constantina Petraki; Alkiviadis Gregorakis; Andreas Scorilas; Panagiotis Papanastasiou; Roxane Tenta; Michael Koutsilieris
Journal:  In Vivo       Date:  2005 Sep-Oct       Impact factor: 2.155

4.  Unrestricted cell cycling and cancer.

Authors:  M Strauss; J Lukas; J Bartek
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

Review 5.  Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.

Authors:  Sunil Singhal; Anil Vachani; Danielle Antin-Ozerkis; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance.

Authors:  A Haitel; H G Wiener; B Neudert; M Marberger; M Susani
Journal:  Urology       Date:  2001-09       Impact factor: 2.649

7.  Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.

Authors:  T Sejima; I Miyagawa
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

8.  Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters.

Authors:  Ylva Hedberg; Göran Roos; Börje Ljungberg; Göran Landberg
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

9.  Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D.

Authors:  Ylva Hedberg; Estela Davoodi; Börje Ljungberg; Göran Roos; Göran Landberg
Journal:  Int J Cancer       Date:  2002-12-20       Impact factor: 7.396

10.  Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray.

Authors:  Y Hedberg; B Ljungberg; G Roos; G Landberg
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more
  2 in total

1.  TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Authors:  Sounak Gupta; Sarah H Johnson; George Vasmatzis; Binu Porath; Jeannette G Rustin; Priya Rao; Brian A Costello; Bradley C Leibovich; R Houston Thompson; John C Cheville; William R Sukov
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

2.  Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.

Authors:  Eva Juengel; Jasmina Makarević; Igor Tsaur; Georg Bartsch; Karen Nelson; Axel Haferkamp; Roman A Blaheta
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.